about
The path for metal complexes to a DNA targetRu-TAP complexes and DNA: from photo-induced electron transfer to gene photo-silencing in living cellsRedox activation of metal-based prodrugs as a strategy for drug deliveryHexammineruthenium(III) ion interactions with Z-DNAUnusual mode of protein binding by a cytotoxic π-arene ruthenium(ii) piano-stool compound containing an O,S-chelating ligandStriking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocyclesDibutyltin(IV) complexes containing arylazobenzoate ligands: chemistry, in vitro cytotoxic effects on human tumor cell lines and mode of interaction with some enzymes.Unusual DNA binding modes for metal anticancer complexes.Osmium(VI) complexes as a new class of potential anti-cancer agents.Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing C(∧)N-Chelated and Pyridine Ligands.Anticancer Activity of Self-Assembled Molecular Rectangles via Arene-Ruthenium Acceptors and a New Unsymmetrical Amide LigandOsmium(IV) complexes with 1H- and 2H-indazoles: tautomer identity versus spectroscopic properties and antiproliferative activity.Application of imaging mass spectrometry approaches to facilitate metal-based anticancer drug research.Comparative solution equilibrium studies of antitumor ruthenium(η6-p-cymene) and rhodium(η5-C5Me5) complexes of 8-hydroxyquinolines.Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects.Modeling anticancer drug-DNA interactions via mixed QM/MM molecular dynamics simulations.Discovery of 8-methoxypyrazino[1,2-a]indole as a New Potent Antiproliferative Agent Against Human Leukemia K562 Cells. A Structure-Activity Relationship Study.Antimetastatic activity of novel ruthenium (III) pyridine complexes.The medicinal applications of imidazolium carbene-metal complexes.Neutron activation increases activity of ruthenium-based complexes and induces cell death in glioma cells independent of p53 tumor suppressor gene.Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action.Tuning heavy metal compounds for anti-tumor activity: is diversity the key to ruthenium's success?Ruthenium(II) polypyridyl complexes and DNA--from structural probes to cellular imaging and therapeutics.Hyphenated techniques as tools for speciation analysis of metal-based pharmaceuticals: developments and applications.Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs.The use of X-ray absorption and synchrotron based micro-X-ray fluorescence spectroscopy to investigate anti-cancer metal compounds in vivo and in vitro.Novel lead structures and activation mechanisms for CO-releasing molecules (CORMs)Metal complex interactions with DNA.Diruthenium(ii,iii) metallodrugs of ibuprofen and naproxen encapsulated in intravenously injectable polymer-lipid nanoparticles exhibit enhanced activity against breast and prostate cancer cells.Metal-based drugs that break the rules.Combining a Ru(ii)-arene complex with a NO-releasing nitrate-ester ligand generates cytotoxic activity.Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.A Cytostatic Ruthenium(II)-Platinum(II) Bis(terpyridyl) Anticancer Complex That Blocks Entry into S Phase by Up-regulating p27(KIP1).Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.Ruthenium (II) complexes interact with human serum albumin and induce apoptosis of tumor cells.Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential.A TrxR inhibiting gold(I) NHC complex induces apoptosis through ASK1-p38-MAPK signaling in pancreatic cancer cells.NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels.Growth inhibitory effects of the Diruthenium-Ibuprofen compound, [Ru2Cl(Ibp) 4], in human glioma cells in vitro and in the rat C6 orthotopic glioma in vivo.
P2860
Q26999667-579621A5-FD09-48D7-BEC9-2E663A06D027Q27014967-B1F1FB17-48D4-4F05-AA87-C0B6BF6DD2E0Q27025736-9F43388B-2091-4E69-92A8-77F40C0DC509Q27649346-A65510F3-777A-417A-B1BE-7FF097C2E669Q27720200-5AEA8962-84BD-4B8C-8D1D-3F6614C436EEQ30623124-B1E175A5-E2E4-4BC7-9A1D-85E0EBB13F13Q33518618-8F3D3B70-5DF7-4946-9E63-5A75E20396C0Q34071185-B92079D8-012B-43C4-8D00-FFC138A6F68BQ34157363-21FFD191-7573-4F29-9535-D2D17DE511EDQ34331245-DF74495D-E0B4-47C6-B84F-EA508B9EBEADQ35983960-63F1C122-8655-4C34-8BEE-0C847113CB16Q36103771-FC018E48-6D6C-4F61-9D82-151797BBC07BQ36268494-3E89FA7E-A1B9-4DC2-93F8-EBF0B8D76113Q36306039-50DCFEB2-F00C-48D6-8B0A-B041D7C70426Q36364465-740814AA-0985-4BCD-877A-D3B75316150DQ36514784-5310AE9A-7348-435F-AB2D-36BFB847A7EDQ37347859-D694EB3E-8779-4791-92D1-208C2692CBE4Q37373102-F05C39D3-823C-4E0F-90F6-EDAF4D994AA1Q37542176-C99DF2E8-DD59-467D-8864-FBF5BDED03A8Q37703236-34D8FF43-1C62-46EB-A13A-F5589D47E196Q37724010-D530CD67-1927-40EA-AE5B-9B131D1A1E55Q37855894-F80FEA3C-0646-4A56-B2D3-B462577E7299Q37982323-C171DDD0-91F6-4AFB-ADD1-D8F5D40E30CBQ38000483-205F72A4-E609-48B0-9164-3DD91285D04AQ38011996-6FA4F51B-4269-4BFF-B6DB-BC4164A011AAQ38096196-EEFE0397-8A44-4621-AD58-E8ADF55EC4F2Q38195891-EF2B2EBE-E7B3-48BE-B272-3E8D5ED68537Q38271731-20546CE5-E50C-4BE3-AD3B-37B849CC0178Q38662609-F8DFBB62-E740-4259-9683-13FAAC83B9EFQ38714812-D55BFF71-6674-487E-9951-02A286A5F430Q38734166-0517946D-2086-49A6-9469-9BDE401C0808Q38776872-8901869E-CA2D-46DD-96BB-469D083A4C67Q38860575-43454EA4-8746-4FE9-9D37-5724FED47F14Q38878220-57789A27-432E-42DD-84A6-D9678BE1CC5AQ38930683-5C33C3AE-682D-4167-8000-7C716523F1BCQ38940330-3DF56463-ADD4-4300-982F-115E52ED3202Q38941379-9DF1C833-AFC0-4EBC-A554-FC5274102267Q38953565-949AF2B6-38F9-402E-B5B5-F2C1FAE7E8A2Q38979908-0252A956-F443-4FF6-90EC-8094952AD493Q38995385-683FE34E-DA9E-4ECD-9EC7-C0A6BE54ADB8
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Ruthenium antimetastatic agents.
@ast
Ruthenium antimetastatic agents.
@en
type
label
Ruthenium antimetastatic agents.
@ast
Ruthenium antimetastatic agents.
@en
prefLabel
Ruthenium antimetastatic agents.
@ast
Ruthenium antimetastatic agents.
@en
P356
P1476
Ruthenium antimetastatic agents.
@en
P2093
Alberta Bergamo
Giovanni Mestroni
P304
P356
10.2174/1568026043387421
P577
2004-01-01T00:00:00Z